DBVT News and Press, DBV Technologies S.A. From 03/24/23

Montrouge, France, March 24, 2023 Ordinary and Extraordinary General Meeting of April 12, 2023 Procedures for Obtaining Information and Preparatory Documents for the General Meeting DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock M...

Montrouge, France, March 13, 2023 DBV Technologies Update DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Market: DBVT), a clinical-stage biopharmaceutical company, informs its investors that it does not hold cash deposits or securities at Silicon Valle...

2023-03-08 16:05:11 ET A French %Biotech firm saw its shares rally strongly on Wednesday after the company announced that the first patient has been screened in the Company’s VITESSE (Viaskin Peanut Immunotherapy Trial to Evaluate Safety Simplicity and Efficacy) Phase 3 clinical ...

Montrouge, France, March 7, 2023 DBV Technologies Announces First Patient Screen ed in VITESSE Phase 3 Clinical Trial in Peanut - Allergic Children 4 – 7 Years Old First patient screened at Midwest Allergy Sinus Asthma in Normal, Illino...

2023-03-06 08:32:34 ET BridgeBio Pharma ( BBIO ) +57% Announces Positive Phase 2 Cohort 5 Results of Infigratinib in Achondroplasia Demonstrating Mean Increase in Annualized Height Velocity of 3.03 cm/year with No Treatment-related Adverse Events. TCR2 Therapeutics ...

DBV Technologies S.A. (DBVT) Q4 2022 Results Conference Call March 02, 2023 05:00 PM ET Company Participants Anne Pollak - Head IR Daniel Tassé - CEO Sébastien Robitaille - CFO Pharis Mohideen - Chief Medical Officer Conference Call Participants ...

Montrouge, France, March 2, 2023 DBV Techn ologies a nnounces f iling of 202 2 Annual Report on Form 10-K and 202 2 Universal Registration Document DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBV...

DBV Technologies press release ( NASDAQ: DBVT ): Q4 GAAP EPS of -$1.24. Revenue of $4.8M (-15.8% Y/Y). For further details see: DBV Technologies GAAP EPS of -$1.24, revenue of $4.8M

Montrouge, France, March 2, 2023 DBV Technologies Reports Full Year 2022 Financial Results and Business Update DBV completed EVOLVE, a 12-week caregiver and patient user experience study of the modified Viaskin Peanut patch in peanut-allergic children ages 4 – 11 years old ...

Montrouge, France, February 27, 2023 DBV Technologies to Report Full Year 202 2 Financial Results and Business Updates on March 2 , 202 3 DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT), a clinical-stage biopharma...